Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Time to Sell?

Key Points

• Telix Pharmaceuticals shares fell sharply: The stock opened at $12.22 versus a prior close of $12.83 and later traded near $11.71.
• Analysts remain broadly positive: Telix has a consensus “Moderate Buy” rating and an average price target of $20.40, despite one recent downgrade to “Sector Perform.”
• Institutional interest increased: Several investment firms expanded their positions, while Telix’s financial metrics included a 2.01 current ratio and a 1.16 debt-to-equity ratio.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $12.83, but opened at $12.22. Telix Pharmaceuticals shares last traded at $11.7050, with a volume of 138,711 shares traded.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Citigroup reaffirmed a "buy" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Royal Bank Of Canada downgraded Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research report on Friday, July 17th. HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a report on Tuesday. Weiss Ratings upgraded Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a research report on Friday, August 21st. Finally, Wedbush reaffirmed an "outperform" rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Telix Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $20.40.

Telix Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85. The stock's 50-day moving average is $11.25 and its two-hundred day moving average is $10.24.

Institutional Investors Weigh In On Telix Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE boosted its stake in shares of Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock valued at $96,000 after purchasing an additional 8,423 shares during the period. XY Capital Ltd purchased a new position in Telix Pharmaceuticals in the 1st quarter worth about $120,000. Lazard Asset Management LLC increased its stake in Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company's stock worth $2,775,000 after buying an additional 39,400 shares during the period. Private Advisor Group LLC lifted its holdings in Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock valued at $1,669,000 after buying an additional 128,070 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in Telix Pharmaceuticals during the 2nd quarter valued at about $1,731,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company's commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.